Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost‐identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

Adding temozolomide (TMZ) to standard radiotherapy as a first‐line therapy for glioma may increase costs to a disproportionate degree compared with the resulting survival benefits.